Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR's share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$12.48 and traded as high as C$12.89. Cipher Pharmaceuticals shares last traded at C$12.49, with a volume of 43,554 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group set a C$12.50 target price on shares of Cipher Pharmaceuticals and gave the company a "hold" rating in a report on Monday, April 7th.
View Our Latest Stock Analysis on CPH
Cipher Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67. The company has a market cap of C$224.06 million, a P/E ratio of 13.78 and a beta of 1.20. The stock has a fifty day moving average price of C$12.49 and a two-hundred day moving average price of C$13.39.
Insiders Place Their Bets
In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin sold 3,500 shares of Cipher Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of C$13.49, for a total value of C$47,215.00. 42.00% of the stock is owned by insiders.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.
Further Reading
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
